StockData

Scynexis vs Zentalis Pharmaceuticals

SCYX and ZNTL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SCYX and ZNTL compare

Zentalis Pharmaceuticals is the larger company, worth 3.8 times as much as Scynexis ($107M against $28.4M).

Scynexis scores higher on the StockData Score (13 against 6 for Zentalis Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSCYXZNTL
Size and price
Market cap$28.4M$107M
Share price$2.85$1.49
Change, 1 year−39.2%12.0%
Change, 5 years−95.2%−98.0%
Beta (5Y)1.585.80
Employees18106
StockData Score
Total score13 (better)6
Valuation score3 (better)1
Growth score2 (better)0
Performance score3 (better)0
Health score55
Dividend score00
Valuation
P/S1.5×–
P/B0.4× (better)0.7×
FCF yield–−120%
Fair value$10.05–
Margin of safety71.6%–
Growth
Revenue growth (TTM)490%–
Profitability
Operating margin−118%–
Net margin−53.3%–
Return on equity−18.4% (better)−66.7%
Financial health
Debt / equity0.000.00
Current ratio9.65 (better)4.82
Altman Z-score−5.27 (better)−8.91
Piotroski F-score5 (better)1
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions51.7%66.1%
Held by insiders24.8%58.0%
Insider net buying, 12 months–$12.8M
Short interest, % of float6.0%16.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.